|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin B, Song X, Yang D, Bai D, Yao Y and Lu
N: Anlotinib inhibits angiogenesis via suppressing the activation
of VEGFR2, PDGFRβ and FGFR1. Gene. 654:77–86. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Han BH, Li K, Wang Q, Zhang L, Shi J, Wang
Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of Anlotinib as a
third-line or further treatment on overall survival of patients
with advanced non-small cell lung cancer: The ALTER 0303 phase 3
randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu D, Nie J, Dai L, Hu W, Zhang J, Chen X,
Ma X, Tian G, Han J, Han S, et al: Salvage treatment with anlotinib
for advanced non-small cell lung cancer. Thorac Cancer.
10:1590–1596. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y
and Lou L: Preclinical characterization of anlotinib, a highly
potent and selective vascular endothelial growth factor receptor-2
inhibitor. Cancer Sci. 109:1207–1219. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu
P, Wang L, Xia Y, Qiao Y, Sun W, et al: Autophagy inhibition
potentiates the anti-angiogenic property of multikinase inhibitor
anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung
cancer cells. J Exp Clin Cancer Res. 38:712019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu J, Zhong H, Chu T, Zhang X, Li R, Sun
J, Zhong R, Yang Y, Alam MS, Lou Y, et al: Role of
anlotinib-induced CCL2 decrease in anti-angiogenesis and response
prediction for nonsmall cell lung cancer therapy. Eur Respir J.
53:2019. View Article : Google Scholar
|
|
8
|
Wang J, Zhao Y, Wang Q, Zhang L, Shi J,
Wang Z, Cheng Y, He J, Shi Y, Yu H, et al: Prognostic factors of
refractory NSCLC patients receiving anlotinib hydrochloride as the
third- or further-line treatment. Cancer Biol Med. 15:443–451.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
No authors listed, . Chinese guidelines
for diagnosis and treatment of primary lung cancer 2018 (English
version). Chin J Cancer Res. 31:1–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li SJ, Fan J, Zhou J, Ren YT, Shen C and
Che GW: Diabetes mellitus and risk of bronchopleural fistula after
pulmonary resections: A meta-analysis. Ann Thorac Surg.
102:328–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okuda M, Go T and Yokomise H: Risk factor
of bronchopleural fistula after general thoracic surgery: Review
article. Gen Thorac Cardiovasc Surg. 65:679–685. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang JY, Verma V, Li M, Zhang W, Komaki
R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, et al: Proton beam
radiotherapy and concurrent chemotherapy for unresectable stage III
non-small cell lung cancer: Final results of a phase 2 study. JAMA
Oncol. 3:e1720322017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng A, Yang X, Ye X, Huang G, Wei Z,
Wang J, Han X, Ni X and Meng M: Bronchopleural fistula after lung
ablation: Experience in two cases and literature review. Indian J
Cancer. 52 (Suppl 2):e41–e46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peters NA, Richel DJ, Verhoeff JJ and
Stalpers LJ: Bowel perforation after radiotherapy in a patient
receiving sorafenib. J Clin Oncol. 26:2405–2406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inoue T, Kinoshita H, Komai Y, Kawabata T,
Kawa G, Uemura Y and Matsuda T: Two cases of gastrointestinal
perforation after radiotherapy in patients receiving tyrosine
kinase inhibitor for advanced renal cell carcinoma. World J Surg
Oncol. 10:1672012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li XF, Tan YN, Cao Y, Xu JH, Zheng S and
Yuan Y: A case report of gastrointestinal hemorrhage and
perforation during apatinib treatment of gastric cancer. Medicine
(Baltimore). 94:e16612015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ou SH, Ahn JS, De Petris L, Govindan R,
Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, et
al: Alectinib in crizotinib-refractory ALK-rearranged
non-small-cell lung cancer: A phase II global study. J Clin Oncol.
34:661–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gennatas S, Stanway SJ, Thomas R, Min T,
Shah R, O'Brien ME and Popat S: Early pneumothorax as a feature of
response to crizotinib therapy in a patient with ALK rearranged
lung adenocarcinoma. BMC Cancer. 13:2072013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katta A, Fesler MJ, Tan A, Vuong G and
Richart JM: Spontaneous bilateral pneumothorax in metastatic renal
cell carcinoma on sunitinib therapy. Cancer Chemother Pharmacol.
66:409–412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang SH, Lin JK, Chen WS, Lin TC, Yang SH,
Jiang JK, Chang SC, Lan YT, Chao TC, Yen CC, et al: Pneumothorax
after bevacizumab-containing chemotherapy: A case report. Jpn J
Clin Oncol. 41:269–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Yang H, Zhao M and He X:
Bilateral pneumothorax after bevacizumab-containing chemotherapy in
fibrosarcoma. J Thorac Dis. 4:229–231. 2012.PubMed/NCBI
|
|
22
|
Makino T, Kudo S and Ogata T: Pneumothorax
after treatment with bevacizumab-containing chemotherapy for breast
cancer-a case report. Gan To Kagaku Ryoho. 41:233–235. 2014.(In
Japanese). PubMed/NCBI
|
|
23
|
Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang
G, Du F, Sun Y, Wu Q, Qu G, et al: Safety and efficacy of
anlotinib, a multikinase angiogenesis inhibitor, in patients with
refractory metastatic soft-tissue sarcoma. Clin Cancer Res.
24:5233–5238. 2018.PubMed/NCBI
|
